Atlas Trials

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Clinical trial NCT06092645 · UNKNOWN

Trial details

NCT number
NCT06092645
Sponsor
Zhejiang Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Bile Duct Adenocarcinoma
Start date
2023-10-30
Primary completion
2024-10-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.